The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory CommitteeElı́as Campo, Ari Melnick, Andrew D. Zelenetz et al.|Blood|2022Cited by 1.5k
Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108Paul M. Barr, Jonathan W. Friedberg|Journal of Clinical Oncology|2015Cited by 111
Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib/II study.Susan O’Brien, Jennifer R. Brown, Jacqueline C. Barrientos et al.|Journal of Clinical Oncology|2012Cited by 36
Prognostic Impact of Cell of Origin in Limited-Stage Diffuse Large B-Cell Lymphoma Treated With R-CHOP With or Without Radiation TherapyPaul Youn, Louis S. Constine, Michael Cummings et al.|International Journal of Radiation Oncology*Biology*Physics|2016Cited by 1
Early Stage Large B-cell Lymphoma in the Rituximab-CHOP +/- Radiation Era: Tailored Therapy Provides Excellent OutcomeS. Dhakal, Louis S. Constine, Manzurul A. Sikder et al.|International Journal of Radiation Oncology*Biology*Physics|2009Cited by 0